1
|
Billings CG, Lewis R, Hurdman JA, Condliffe R, Elliot CA, Thompson AR, Smith IA, Austin M, Armstrong IJ, Hamilton N, Charalampopoulos A, Sabroe I, Swift AJ, Rothman AM, Wild JM, Lawrie A, Waterhouse JC, Kiely DG. The incremental shuttle walk test predicts mortality in non-group 1 pulmonary hypertension: results from the ASPIRE Registry. Pulm Circ 2019; 9:2045894019848649. [PMID: 30997865 PMCID: PMC6542131 DOI: 10.1177/2045894019848649] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/31/2018] [Accepted: 04/09/2019] [Indexed: 11/16/2022] Open
Abstract
Pulmonary hypertension (PH) is classified into five groups based on disease etiology but there is only limited information on the prognostic value of exercise testing in non-group 1 PH. In group 1 PH, the incremental shuttle walking test (ISWT) distance has been shown to correlate with pulmonary hemodynamics and predict survival without a ceiling effect. This study assessed the ISWT in non-group 1 PH. Data were retrieved from the ASPIRE Registry (Assessing the Spectrum of Pulmonary hypertension Identified at a REferral centre) for consecutive patients diagnosed with PH. Patients were required to have been systematically assessed as group 2-5 PH and to have a baseline ISWT within three months of cardiac catheterization. Patients were stratified according to incremental shuttle walk test distance (ISWD) and ISWT distance percent predicted (ISWD%pred). A total of 479 patients with non-group 1 PH were identified. ISWD and ISWD%pred correlated significantly with symptoms and hemodynamic severity. ISWD and ISWD%pred predicted survival with no ceiling effect. The test was prognostic in groups 2, 3, and 4. ISWD and ISWD%pred and change in ISWD and ISWD%pred at one year were all significant predictors of outcome. In patients with non-group 1 PH the ISWT is a simple non-invasive test that is easy to perform, is predictive of survival at baseline and follow-up, reflects change, and can be used in the assessment of PH of any etiology.
Collapse
Affiliation(s)
- Catherine G. Billings
- Sheffield Pulmonary Vascular Disease
Unit,
Sheffield
Teaching Hospitals NHS Foundation Trust,
Royal
Hallamshire Hospital, Sheffield, UK
| | - Robert Lewis
- Sheffield Pulmonary Vascular Disease
Unit,
Sheffield
Teaching Hospitals NHS Foundation Trust,
Royal
Hallamshire Hospital, Sheffield, UK
- Department of Infection, Immunity and
Cardiovascular Disease, University of Sheffield, Medical School, Sheffield, UK
| | - Judith A. Hurdman
- Sheffield Pulmonary Vascular Disease
Unit,
Sheffield
Teaching Hospitals NHS Foundation Trust,
Royal
Hallamshire Hospital, Sheffield, UK
| | - Robin Condliffe
- Sheffield Pulmonary Vascular Disease
Unit,
Sheffield
Teaching Hospitals NHS Foundation Trust,
Royal
Hallamshire Hospital, Sheffield, UK
| | - Charlie A. Elliot
- Sheffield Pulmonary Vascular Disease
Unit,
Sheffield
Teaching Hospitals NHS Foundation Trust,
Royal
Hallamshire Hospital, Sheffield, UK
| | - A.A. Roger Thompson
- Sheffield Pulmonary Vascular Disease
Unit,
Sheffield
Teaching Hospitals NHS Foundation Trust,
Royal
Hallamshire Hospital, Sheffield, UK
- Department of Infection, Immunity and
Cardiovascular Disease, University of Sheffield, Medical School, Sheffield, UK
| | - Ian A. Smith
- Sheffield Pulmonary Vascular Disease
Unit,
Sheffield
Teaching Hospitals NHS Foundation Trust,
Royal
Hallamshire Hospital, Sheffield, UK
| | - Matthew Austin
- Sheffield Pulmonary Vascular Disease
Unit,
Sheffield
Teaching Hospitals NHS Foundation Trust,
Royal
Hallamshire Hospital, Sheffield, UK
| | - Iain J. Armstrong
- Sheffield Pulmonary Vascular Disease
Unit,
Sheffield
Teaching Hospitals NHS Foundation Trust,
Royal
Hallamshire Hospital, Sheffield, UK
| | - Neil Hamilton
- Sheffield Pulmonary Vascular Disease
Unit,
Sheffield
Teaching Hospitals NHS Foundation Trust,
Royal
Hallamshire Hospital, Sheffield, UK
| | - Athanasios Charalampopoulos
- Sheffield Pulmonary Vascular Disease
Unit,
Sheffield
Teaching Hospitals NHS Foundation Trust,
Royal
Hallamshire Hospital, Sheffield, UK
| | - Ian Sabroe
- Sheffield Pulmonary Vascular Disease
Unit,
Sheffield
Teaching Hospitals NHS Foundation Trust,
Royal
Hallamshire Hospital, Sheffield, UK
- Department of Infection, Immunity and
Cardiovascular Disease, University of Sheffield, Medical School, Sheffield, UK
| | - Andrew J. Swift
- Department of Infection, Immunity and
Cardiovascular Disease, University of Sheffield, Medical School, Sheffield, UK
- Insigneo Institute for in
silico Medicine, University of Sheffield, The Pam Liversidge Building,
Sir Frederick Mappin Building, Sheffield, UK
| | - Alexander M. Rothman
- Department of Infection, Immunity and
Cardiovascular Disease, University of Sheffield, Medical School, Sheffield, UK
| | - Jim M. Wild
- Department of Infection, Immunity and
Cardiovascular Disease, University of Sheffield, Medical School, Sheffield, UK
- Insigneo Institute for in
silico Medicine, University of Sheffield, The Pam Liversidge Building,
Sir Frederick Mappin Building, Sheffield, UK
| | - Allan Lawrie
- Department of Infection, Immunity and
Cardiovascular Disease, University of Sheffield, Medical School, Sheffield, UK
| | - Judith C. Waterhouse
- Sheffield Pulmonary Vascular Disease
Unit,
Sheffield
Teaching Hospitals NHS Foundation Trust,
Royal
Hallamshire Hospital, Sheffield, UK
| | - David G. Kiely
- Sheffield Pulmonary Vascular Disease
Unit,
Sheffield
Teaching Hospitals NHS Foundation Trust,
Royal
Hallamshire Hospital, Sheffield, UK
- Department of Infection, Immunity and
Cardiovascular Disease, University of Sheffield, Medical School, Sheffield, UK
- Insigneo Institute for in
silico Medicine, University of Sheffield, The Pam Liversidge Building,
Sir Frederick Mappin Building, Sheffield, UK
| |
Collapse
|